Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 8/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.35 |
| ▸ | KDR | P35968 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124334 | 0.80 | MEN1 (0.40) | MEN1KMT2AFGFR1FGFR2FGFR4 | |
| SCHEMBL2127087 | 0.79 | KCNA5 (0.36) | MEN1KMT2AFGFR1FGFR2FGFR4 | |
| SCHEMBL2693716 | 0.79 | KMT2A (0.39) | MEN1KMT2AFGFR1FGFR2FGFR4 | |
| SCHEMBL4070185 | 0.76 | ALDH1A1 (0.38) | MEN1KMT2AFGFR1FGFR2FGFR4 | |
| SCHEMBL2124123 | 0.76 | MEN1 (0.46) | MEN1KMT2AFGFR1FGFR2FGFR4 | |
| SCHEMBL2130710 | 0.75 | KMT2A (0.33) | MEN1KMT2AFGFR1FGFR2FGFR4 | |
| SCHEMBL2692934 | 0.74 | SYK (0.35) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2695843 | 0.72 | MEN1 (0.34) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2695847 | 0.72 | MEN1 (0.34) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2694563 | 0.71 | NPC1 (0.35) | MEN1KMT2AALDH1A1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519124-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-1961744-B1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8168783-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1961744-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | CXCR4, CXCL12, CXCR3 | MEN1 1493/4885KMT2A 3189/4885FGFR1 210/4885 |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR3, CXCR1 | MEN1 2594/4885KMT2A 3359/4885FGFR1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.